Author
Affilliation
Abstract
Latent tuberculosis infection (LTBI) is characterised by the presence of immune responses to previously acquired Mycobacterium tuberculosis infection without clinical evidence of active tuberculosis (TB). Here we report evidence-based guidelines from the World Health Organization for a public health approach to the management of LTBI in high risk individuals in countries with high or middle upper income and TB incidence of <100 per 100 000 per year. The guidelines strongly recommend systematic testing and treatment of LTBI in people living with HIV, adult and child contacts of pulmonary TB cases, patients initiating anti-tumour necrosis factor treatment, patients receiving dialysis, patients preparing for organ or haematological transplantation, and patients with silicosis. In prisoners, healthcare workers, immigrants from high TB burden countries, homeless persons and illicit drug users, systematic testing and treatment of LTBI is conditionally recommended, according to TB epidemiology and resource availability. Either commercial interferon-gamma release assays or Mantoux tuberculin skin testing could be used to test for LTBI. Chest radiography should be performed before LTBI treatment to rule out active TB disease. Recommended treatment regimens for LTBI include: 6 or 9 month isoniazid; 12 week rifapentine plus isoniazid; 3-4 month isoniazid plus rifampicin; or 3-4 month rifampicin alone.
Publisher
European Respiratory Society
Citation
GETAHUN, Haileyesus et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. European Respiratory Journal, v. 46, p. 1563-1576, 2015.
DOI
10.1183/13993003.01245-2015
ISSN
0903-1936
Notes
Solange Cavalcante. Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
The Global TB Programme, World Health Organization, Geneva, Switzerland. 2 Dept of Infection and Population Health, University College London, London, UK. 3 Public Health England, London, UK. 4 World Health Organization, Regional Office for Eastern Mediterranean, Egypt. 5 National TB Programme, Ministry of Health, Brasilia, Brazil. 6 Independent consultant, Switzerland. 7 Pedro Kourí Institute of Tropical Medicine, La Habana, Cuba. 8 Unit of Infectious Diseases, Dept of Medicine, Karolinska Institute Solna and Karolinska University Hospital, Stockholm, Sweden. 9 Dept of Pulmonology and Respiratory Medicine, Faculty of Medicine, University of Indonesia and Persahabatan Hospital, Jakarta, Indonesia. 10Evandro Chagas National Institute of Infectious Diseases, FIOCRUZ, Rio de Janeiro, Brazil. 11Hospital Nacionale Rosales, San Salvador, El Salvador. 12Center for TB Research, John Hopkins University, Baltimore, MD, USA. 13Tan Tock Seng Hospital, Singapore. 14TB Advocacy Consortium, Nairobi, Kenya. 15London School of Hygiene and Tropical Medicine, Blantyre, Malawi. 16World Health Organization, Regional Office for Europe, Denmark. 17Victorian Tuberculosis Program, Melbourne, Australia. 18KNCV Tuberculosis Foundation, Den Haag, The Netherlands. 19Dept of HIV and Global Hepatitis Programme, World Health Organization, Switzerland. 20Public Health Agency of Canada, Ottawa, ON, Canada. 21Istituto Nazionale Malattie Infettive L. Spallanzani, Rome, Italy. 22Dept of HIV/AIDS and TB Control Korea, Korea Centers for Disease Control and Prevention, Republic of Korea. 23Health Systems Research Unit, South African Medical Research Council, South Africa. 24Dept of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK. 25Dept of Epidemiology, Boston University School of Public Health, Boston, MA, USA. 26Main Medical Department, Ministry of Justice, Azerbaijan. 27McGill International TB Centre, and Dept of Epidemiology and Biostatistics, McGill University, Montreal, QC, Canada. 28Centers for Disease Control and Prevention, USA. 29Dept of Public Health Sciences, Karolinska Institute, Solna, Sweden. 30Woolcock Institute of Medical Research University of Sydney and UNSW Australia, Sydney, Australia. 31WHO Collaborating Center for TB and Lung Diseases Fondazione S. Maugeri, Tradate, Italy. 32Migration Health Department, International Organization of Migration, Geneva, Switzerland. 33Infectious Disease Division, Bureau for Global Health, US Agency for International Development, Washington, DC, USA. 34Zambart Project, Lusaka, Zambia. 35World Health Organization, Regional Office for the Western Pacific, Philippines. 36Pallas Health Research and Consultancy BV, Rotterdam, The Netherlands. 37Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa. 38Knowledge, Ethics and Research Department, World Health Organization, Switzerland. 39European Centre for Disease Prevention and Control, Stockholm, Sweden. 40Dept of Clinical Epidemiology and Biostatistics and Dept of Medicine, GRADE Center, McMaster University, Hamilton, ON, Canada. 41Dept of Medicine, All India Institute of Medical Sciences, New Delhi, India. 42Sassari University, Sassari, Italy. 43Vanderbilt University School of Medicine, Nashville, TN, USA. 44National TB Programme, Ministry of Health, Riyadh, Saudi Arabia. 45European AIDS Treatment Group, Brussels, Belgium. 46Academic Medical Centre, University of Amsterdam, Dept of Global Health, Amsterdam, The Netherlands. 47HIV/TB and Penal System Projects, Russian Federation. 48Clinical Laboratories, Ministry of Health, Nicosia, Cyprus. 49Francis Crick Institute Mill Hill Laboratory, Dept of Medicine, Imperial College London, London, UK. 50Fukujuji Hospital, Japan Anti Tuberculosis Association, Tokyo, Japan. 51Tuberculosis Competence Centre, Berne, Switzerland.
Share